Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Apr 14, 2009
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
Antioxidant enzymes are proteins produced by the body to protect cells against the harmful effects of chemicals, such as those found in air pollution. Particulate air pollution and diesel exhaust in particular have been shown to cause and also exacerbate allergic airway disease. While there are ongoing efforts to improve air quality, there remains a need for alternative methods to address and prevent the adverse health effects of ambient air pollution, such as allergic rhinitis,, asthma, chronic obstructive pulmonary disease, and lung cancer. Currently, there are no therapeutic options whic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able and willing to provide informed consent
- • DEP responder as defined in protocol
- • Ability to refrain from consuming cruciferous vegetables 3 days prior to starting study and while on study. Cruciferous vegetables include: Broccoli, Kale, Chard, Kohlrabi, Brussels Sprouts, Parsley, Watercress, Daikon, Cabbage, Rutabagas, Cauliflower, Bok Choy, Arugula, Turnips, Radish, Mustard and Collard greens.
- • Allergy skin test positive to cat
- • Nonsmoker or ex-smoker of more than one year
- Exclusion Criteria:
- • Smoking within past year or during study
- • Systemic corticosteroid or other immunosuppressive medication use in the previous 3 months or during study
- • Intranasal corticosteroid use in the previous month or during the study
- • Intranasal antihistamine or cromolyn use in the previous week or during study
- • Allergen immunotherapy during the previous 12 months or during study
- • Omalizumab use in the previous 12 months or during study
- • Systemic antihistamine or leukotriene modifying medication use in the previous week or during study
- • History of asthma or any current medical condition that in the opinion of the investigator may compromise the subject's ability to safely participate in the study
- • Baseline abnormality of hemoglobin, platelets, leukocytes, serum chemistries, liver function testing, or presence of proteinuria
- • A finding during physical examination that, in the opinion of the investigator may compromise the participant's ability to safely participate in the study
- • Pregnant or breast-feeding
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
David Heber, MD, PhD
Study Chair
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials